38.6c New Delhi, India, Friday, August 19, 2022
Top Stories
Interviews Know The Law Book Reviews Videos
About Us Contact Us
Executive

Centre Moves Supreme Court Against Delhi HC Order Over Ban On Oxytocin

By Editor : Shreya Bansal      Feb 05, 2019      0 Comments      508 Views

The Central government has moved the Supreme Court against the Delhi High Court August 31, 2019, verdict in which the High Court had suspended the ban that was imposed by the Centre on the manufacturing, distribution, sale, and import of oxytocin by the private companies in India.

Oxytocin is a uterine stimulant hormone which is used to induce labour during childbirth and control bleeding after it. It is also used to help abort the foetus in case of incomplete abortion or miscarriage.

In April 2018, the government through a notification restricted private companies from manufacturing or supplying the drug (oxytocin) to stop its alleged misuse in the dairy sector, where it was injected into dairy animals to increase their milk production.

As per the notification issued by the Centre, Karnataka Antibiotics and Pharmaceuticals Ltd (KAPL), a government company, was solely allowed to manufacture the drug to meet the needs of the country.

This was challenged in the Delhi High Court in a batch of petitions preferred by NGO – All India Drug Action Network amongst others contending that move was unreasonable and arbitrary.

A Bench comprising of Justice S. Ravindra Bhat and Justice A.K. Chawla had suspended the ban after noting that the Centre “did not weigh in the dangers of concentrating manufacture of Oxytocin with one unit,” and that the decision could lead to restricted supply of the drug, which would have an adverse effect on maternal health.



Tags:
Delhi High Court
Share this article:


Editor : Shreya Bansal
Editor
     



Leave a feedback about this




Related Posts
View All

TRENDING NEWS


TOP STORIES


ADVERTISEMENT


Lawstreet Advertisement

Signup for Our Newsletter

Get Exclusive access to members only content by email